The evidence of CD4+CXCL13+ T cells shaping TME composition may represent a LR-CHL–specific mechanism of immune dysfunction, suggesting that therapeutic targeting of these cells might reverse their immunosuppressive effects (44). The gene discussed is CD4; the disease is immune system disorder.